Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibit...
Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibition in gastric cancer
About this item
Full title
Author / Creator
Xue, Wenjing , Xu, Caili , Zhang, Kaiqi , Cui, Lu , Huang, Xiting , Nan, Yanyang , Ju, Dianwen , Chang, Xusheng and Zhang, Xuyao
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Claudin18.2 (CLDN18.2) is overexpressed in cancers of the digestive system, rendering it an ideal drug target for antibody-drug conjugates (ADCs). Despite many CLDN18.2-directed ADCs undergoing clinical trials, the inconclusive underlying mechanisms pose a hurdle to extending the utility of these agents. In our study, αCLDN18.2-MMAE, an ADC compose...
Alternative Titles
Full title
Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibition in gastric cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_1c6884e23f074c82bad904974747cf43
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1c6884e23f074c82bad904974747cf43
Other Identifiers
ISSN
2058-7716
E-ISSN
2058-7716
DOI
10.1038/s41420-024-02167-0
